# Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

> **NCT01122030** · PHASE2 · COMPLETED · sponsor: **Shionogi** · enrollment: 72 (actual)

## Conditions studied

- Opioid Induced Bowel Dysfunction

## Interventions

- **DRUG:** Naldemedine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01122030
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-19
- **Primary completion:** 2011-02-23
- **Final completion:** 2011-03-22
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122030, "Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01122030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*